title: Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
abstract: Very little progress has been made in the treatment of patients with metastatic squamous cell lung cancer over the past 2 decades. Identification of novel molecular alterations for targeted therapies is necessary to improve outcomes. Advances in genomic technology have now made it possible to analyze the genomic landscape of tumor tissues comprehensively. We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings.
authors.affiliation: Department of Internal Medicine, St. Luke's Hospital, Chesterfield, Missouri, USA.
authors.forename: Siddhartha
authors.initials: S
authors.lastname: Devarakonda
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D030541:Databases, Genetic; D015195:Drug Design; D020022:Genetic Predisposition to Disease; D015894:Genome, Human; D023281:Genomics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D010641:Phenotype; D057285:Precision Medicine; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor